Trials / Completed
CompletedNCT04911894
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
A Phase Ia/Ib, Open-Label, Multi-Center, Study of the Safety, Tolerability and Primary Efficacy of IBI321 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI321 | Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit. |
Timeline
- Start date
- 2021-06-21
- Primary completion
- 2023-01-30
- Completion
- 2023-02-17
- First posted
- 2021-06-03
- Last updated
- 2023-03-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04911894. Inclusion in this directory is not an endorsement.